about
Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profileChromosome 7p11.2 (EGFR) variation influences glioma riskDNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues.Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.NOTCH2 is neither rearranged nor mutated in t(1;19) positive oligodendrogliomas.CRX is a diagnostic marker of retinal and pineal lineage tumorsIDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.Tumor and endothelial cell hybrids participate in glioblastoma vasculature.ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic targetA hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients.DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide.Spatial and temporal evolution of distal 10q deletion, a prognostically unfavorable event in diffuse low-grade gliomas.Genetic risk profiles identify different molecular etiologies for glioma.SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas.TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORA novel tumor suppressor function of Kindlin-3 in solid cancer.Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951TCF12 is mutated in anaplastic oligodendrogliomaDetection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain TumorsMulti-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors.Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomasQuantifying the heritability of glioma using genome-wide complex trait analysis.Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologiesPreclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type GlioblastomasDeciphering the 8q24.21 association for glioma.Low penetrance susceptibility to glioma is caused by the TP53 variant rs78378222.Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies.Array-based genomics in glioma research.Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas.Insights revealed by high-throughput genomic arrays in nonglial primary brain tumors.MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951.Predictive biomarkers investigated in glioblastoma.Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity.Chains of magnetosomes with controlled endotoxin release and partial tumor occupation induce full destruction of intracranial U87-Luc glioma in mice under the application of an alternating magnetic field.Development of non-pyrogenic magnetosome minerals coated with poly-l-lysine leading to full disappearance of intracranial U87-Luc glioblastoma in 100% of treated mice using magnetic hyperthermia.
P50
Q21245722-AA9B8EDF-70A5-41AB-8452-D3CE5E2EE971Q28943530-5DF00164-7889-406B-ACFE-C21392EACC73Q31068101-0CDBA013-96E3-4EBA-A0CB-A51687EC33E0Q31113299-1B33DC3A-E5D7-475B-AB0A-CD0E4A8DE515Q33396947-C6D43E2A-9E8D-4555-9B33-DC74D5D00EBFQ33516561-7F165D2D-9979-4D2B-8E12-CA9D9777A774Q33531623-42F60556-605D-4153-84CB-DE9F4762636BQ33597465-933B25DB-3129-4A44-AB53-B745510200B3Q33634637-1A89FFEC-CB7B-4474-91FD-C097C2789EE1Q34018659-621AA3BA-7E02-460F-B60C-65474E625402Q34149065-8376AFD0-87FF-4A88-B5D8-AE979DB1CD09Q34215037-BC3CC40A-E679-4F3F-AA5B-0C63E4DBD01DQ34332857-F07E8E75-4EA2-4E80-BA32-F835318EB8F6Q34341061-16B89272-A9FA-4EE4-8142-3F5CCDEE07C7Q34446905-19CF5EC9-5111-4B16-B6BA-52F285FD6393Q34499685-6BD2C1CC-54A1-48A5-A5FB-C9F5C6AEF49EQ34505227-14162B68-6D0A-481A-B3D0-F6A7B7014892Q34523475-019F9DC0-4280-44FA-B163-936533286296Q34619189-A99F5A24-5562-40A0-BD53-AD8B55559F7CQ34990522-FEFEE4F1-B68D-4DED-8A43-1E772B7CB416Q35813648-53DACF17-A3A9-4A2E-96CF-DBF61CA52C4BQ35862636-3BD9923B-189C-4CD0-A00B-4475C3E75DDEQ36069167-E1CFEA7B-A8B6-4EA9-BF46-4F8998810BACQ36116146-DD308F8C-85CE-4BB6-939F-4DCE089F7F0AQ36196936-E7FDB8C3-F178-4BD8-ADFA-D692492EF38BQ36340335-8C2C442F-9E87-4D84-A818-9A8ECF9F1739Q36618241-14D84762-C70C-4C02-9653-3D2B8E18F52EQ36792720-42E8FD38-1F30-4F13-AFDA-5190C8389B8FQ36828178-F95E8C3A-340F-4916-B2A5-324AB27BB754Q36839027-8930CBA3-2941-4DBB-B251-048848BAD4A3Q36896094-201589D4-F407-4B58-BB5E-73CD86327999Q37225334-2EB374E1-9B7A-478A-BEA1-ED80BC6D1684Q37418245-E074D5E3-75D4-46C7-AE3D-D03835A4093DQ37580501-89BFFFB2-F3D1-4A2C-BF88-19EEFD85C422Q37999071-A2814EB0-2889-48F5-894C-C25E3DA8A067Q38129238-B2F6F85F-6D48-41D7-A526-927B1E665BDBQ38237337-0D1DCAF6-C8DA-41A3-98EA-3E1C4F9EC8B9Q38315813-0DE2856A-F8E1-46B2-9DBC-D250355FB48DQ38369223-A1CB2224-6A5E-49B5-B318-74087541652BQ38369423-78C111D2-1AFE-4345-9C4A-731B0CFAEEBB
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ahmed Idbaih
@ast
Ahmed Idbaih
@en
Ahmed Idbaih
@es
Ahmed Idbaih
@nl
Ahmed Idbaih
@sl
type
label
Ahmed Idbaih
@ast
Ahmed Idbaih
@en
Ahmed Idbaih
@es
Ahmed Idbaih
@nl
Ahmed Idbaih
@sl
prefLabel
Ahmed Idbaih
@ast
Ahmed Idbaih
@en
Ahmed Idbaih
@es
Ahmed Idbaih
@nl
Ahmed Idbaih
@sl
P108
P1053
N-8746-2017
P106
P1153
22134879200
P21
P31
P496
0000-0001-5290-1204